Jacobs Levy Equity Management’s Alaunos Therapeutics TCRT Stock Holding History

Jacobs Levy Equity Management’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,181	Closed	-$679K	–	1076
2023 Q1	$679K	Buy	+7,181	New	+$684K	﹤0.01%	762
2014 Q2	–	Sell	-587	Closed	-$403K	–	927
2014 Q1	$403K	Buy	+587	New	+$393K	0.01%	711

Other funds holding TCRT

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management's TCRT Position: Q2 2023 in Review

Jacobs Levy Equity Management sold out of Alaunos Therapeutics (TCRT) in Q2 2023, closing a stake of 7,181 shares — an estimated $679K sold.

Jacobs Levy Equity Management first reported a position in TCRT in Q1 2014 and held it in 2 quarters. The position peaked at $679K in Q1 2023. 100 funds tracked by Wall St. Rank hold TCRT as of Q2 2023.

Jacobs Levy Equity Management reported no remaining Alaunos Therapeutics position as of Q2 2023 after selling out during the quarter.
Jacobs Levy Equity Management sold 7,181 Alaunos Therapeutics shares in Q2 2023, an estimated $679K.
Jacobs Levy Equity Management first reported a position in Alaunos Therapeutics in Q1 2014 and held it in 2 quarters.
Jacobs Levy Equity Management's Alaunos Therapeutics position peaked at $679K in Q1 2023.
100 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2023.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2023, filed 14 Aug 2023.